Press Release
TRUSTCO APPOINTS INDEPENDENT COMMITTEE TO OVERSEE DELISTING PROCESS
Trustco Group Holdings Limited (“Trustco” or “the Company”) announced that its Board of Directors has established an independent committee to manage the proposed delisting from the Johannesburg Stock Exchange (JSE), Namibian Stock Exchange (NSX), and OTCQX Market in the United States. This follows the Company’s earlier announcement evaluating the delisting in preparation for its planned Nasdaq direct listing.
The newly formed committee comprises entirely of independent non-executive directors and is chaired by the Independent Chairperson of the Board, Advocate Raymond Heathcote SC, who will oversee all aspects of the delisting process. This includes coordinating with regulators, ensuring compliance with the JSE Listings Requirements and Namibian Company Law, facilitating shareholder engagement, and overseeing the preparation of a fairness opinion by an appointed independent expert. The JSE accredited Independent Expert has been engaged to conduct the fairness opinion, with the process already commenced.
Quinton van Rooyen, CEO of Trustco Group Holdings
“The appointment of an independent committee underscores Trustco’s commitment to transparency and equitable treatment of all shareholders during this pivotal transition,” said Quinton van Rooyen, CEO of Trustco Group Holdings. “I have full confidence in the Board’s leadership and the expertise of the appointed committee members to execute this process effectively. Their collective experience and diligence will ensure that the delisting process meets the highest standards, addressing all regulatory requirements and safeguarding shareholder interests as we move towards our Nasdaq listing.”
To ensure continuous and effective communication throughout the transition period between delisting and the planned Nasdaq listing, the Company requests all shareholders to update their contact information through the dedicated shareholder contact form at https://www.tgh.na/shareholder-contact-form/. This will enable Trustco to maintain direct communication channels with its shareholder base during the transition.
Regarding the Company’s financial reporting, Trustco also updated shareholders on the progress of the Annual Financial Statements for Fiscal Year 2024. In line with amended Listings Requirements and the ongoing delisting and uplisting processes, a Public Company Accounting Oversight Board Audit (PCAOB audit) for the historical Annual Financial years ended 31 August 2023 and 31 August 2024 is required. Trustco remains incorporated in Namibia and must comply with home country legislation. Accordingly, the company shall complete the Namibian audit for the AFS FY2024. The audit processes are all underway, and shareholders are advised that the AFS FY2024 shall be published as soon as the Namibian audit has been completed and will form part of the delisting process.
A comprehensive formal offer detailing the proposed delisting and the Nasdaq transition timeline will be distributed to shareholders in due course. Shareholders are advised to exercise caution when dealing in the Company’s securities until a full announcement is made. For any questions or further information, shareholders can send an email to the company secretary at komada@tgh.na.
About Trustco:
Trustco Group Holdings Limited is a holding company headquartered in Windhoek, Namibia, that owns subsidiaries engaged in diverse business activities spanning the real estate, mining, insurance, micro-finance, and education sectors.
Trustco’s ordinary shares are listed in the JSE under the symbol “TTO” and in the NSX under the symbol “TUC.” Trustco’s American Depositary Shares are quoted on the OTCQX through its ADR program under the symbol “TSCHY.”
About Namibia:
Namibia is a Southern African country with a population of approximately three million and a GDP per capita of USD 5031 in 2022. The country is endowed with rich natural resources, with recent major discoveries of oil and gas reserves, lithium deposits and rare earth minerals that are vital for technology demand globally, with developments also underway in its green hydrogen projects. The Namibian government has heralded these discoveries as a transformative period, holding the potential to double the nation’s GDP by 2040.
The country’s economy expanded by 4.2% in 2023 and is projected to expand by 3.1% in 2024 and 3.9% in 2025, following a recovery of 5.3% in 2022 from the COVID-19 pandemic. With its wealth of natural resources, pro-business environment, political stability and increasingly skilled workforce, Namibia offers attractive investment prospects across all sectors.
Forward-Looking Statements:
All statements made in this media release with respect to Trustco’s current plans, estimates, strategies beliefs and other statements that are not historical facts, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these words or other similar terms or expressions. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.
Media Contact
Organization: Trustco Group Holdings
Contact Person: Neville Basson
Website: https://www.tgh.na
Email: Send Email
Contact Number: +264612754501
Address: 2 Keller Street, Trustco House
Address 2: Windhoek
City: Windhoek
State: Khomas
Country: Namibia
Release Id: 04022523302
The post TRUSTCO APPOINTS INDEPENDENT COMMITTEE TO OVERSEE DELISTING PROCESS appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
LF Labs is extending its Web3 influence with a global PoS rollout and 20 new exchange listings on July 30, driving LF Coin toward $1 by that milestone.
Strong Expansion Bolsters Market Confidence
Dubai, UAE, 6th July 2025, ZEX PR WIRE, LF Labs (LF Coin) is gearing up for a major milestone on July 30, when it will secure listings on 20 additional exchanges. This move underscores LF Labs’ commitment to building a comprehensive Web3 infrastructure, and it arrives just as LF Coin gains traction in both utility and market sentiment.
Market Momentum and Technical Outlook
On July 1, LF Coin rallied 29% in one day to close at 0.0007793 USDT, accompanied by a surge in trading volume and a shift toward bullish technical indicators. According to the 4-Hour analysis chart, LF/USDT has broken out above its rising EMA, with a bullish MACD crossover and RSI popping above 70, signaling fresh upside momentum. Expect a run toward 0.00085 USDT—and potentially 0.0010—if this strength continues.
Source : TradingView
Real-World Utility Fuels Demand
LF Labs is preparing to deploy blockchain-powered PoS machines that facilitate instant crypto-to-fiat conversions for merchants worldwide. Early pre-bookings suggest strong merchant interest, and each transaction processed through these devices is designed to increase demand for LF Coin as we approach the July 30 listings. In tandem with its PoS terminals, LF Labs also offers the LF Wallet, a secure, user-friendly app that lets merchants and consumers store, send and receive LF Coin seamlessly—and automatically routes funds through the PoS devices for instant crypto-to-fiat settlements.
Integrated Ecosystem Addresses Industry Fragmentation
By offering a full stack of solutions—from project acceleration and market-making to seamless payment infrastructure—LF Labs aims to bridge gaps across the crypto industry. As highlighted in its recent announcement on X (formerly Twitter), LF Labs Token, this integrated approach provides tangible utility beyond what many speculative tokens can claim.
Technical Milestones Point to $1 Target
Analysts are closely watching the 0.000740 USDT resistance level. A decisive break and sustained hold above this threshold could open the door to the psychological 0.001000 USDT mark, setting the stage for the $1 target by the July 30 exchange listings. Support near 0.000580 USDT remains firm, offering a solid base for further gains.
Anniversary Listings to Enhance Liquidity
To mark its fourth anniversary on July 30, LF Labs is orchestrating simultaneous listings across 20 exchanges. This expanded market access is expected to deepen liquidity, broaden investor participation, and reinforce the upward trajectory of LF Coin.
Sustainable Growth Through Low Frequency Accelerator
Beyond infrastructure, LF Labs supports emerging blockchain startups via its Low Frequency Accelerator, providing capital, liquidity, and technical expertise. This end-to-end support not only strengthens the broader ecosystem but also channels additional demand back into LF Coin.
Conclusion
With robust technical signals, real-world utility, and a strategic expansion plan—including global PoS deployment and 20 exchange listings on July 30—LF Labs is primed for a potential surge toward the $1 mark by that very milestone.
Frequently Asked Questions
- What is LF Coin?
LF Coin is LF Labs’ native utility token, powering transactions within its PoS ecosystem, rewarding network participants, and enabling staking for governance. - How can I buy LF Coin?
You can purchase it using USDT or other major trading pairs on any supported platform such as Gate.io, HTX, and MEXC. - What are LF Labs PoS machines?
These are blockchain-powered point-of-sale terminals that convert cryptocurrencies into local fiat in real time, designed for merchants seeking seamless Web3 payment solutions. - How do I pre-book a PoS machine?
You can pre-book through the LF Labs website now. - Where and when will LF Coin be listed?
LF Coin listings go live simultaneously on July 30 across 20 major centralized exchanges. Check LF Labs’ official channels for the complete exchange roster and trading pairs.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
British Virgin Islands, BVI, 6th July 2025, ZEX PR WIRE, Enterprise-level adoption of AI agents has reached a critical turning point, yet the majority of implementations fail at the execution layer. While current AI agents excel at understanding intent, they consistently struggle to deliver reliable, auditable actions across fragmented multi-chain ecosystems. FlowAgent, developed by Tearline, represents a fundamental breakthrough in bridging this execution gap through transparent, verifiable automation.
It is more than a Web3 automation layer. It’s a transparent, modular, programmable coordination engine — turning high-level intent with natural languages into structured, verifiable action across decentralised networks. And more importantly, it lays the groundwork for a new class of software-native agents: collaborative, auditable, and ready for distributed production.
Execution Infrastructure for the Intent Economy
FlowAgent rethinks how agent systems interface with real-world protocols. Built around a state-visible execution pipeline, it translates user intent into stepwise, auditable workflows. Each operation is encoded as a directed acyclic graph (DAG), enabling developers and users alike to observe and verify execution logic in real time.
Modular Workflows, Composable Behaviour
-
Composable Intelligence: Developers can chain together on-chain operations as structured, state-aware modules.
-
Dynamic Graph Scheduling: Workflows can adapt in-flight based on context, failure state, or cross-agent input.
-
Protocol Extensibility: New chains or components can be integrated without re-architecting the agent runtime.
From Isolated Prompts to Agent Networks
-
Distributed task planning
-
Contextual state and memory sharing
-
Scoped authority and permission-aware delegation
Engineering Breakthrough: Orchestration at Scale
From Web3 Automation to System-Level Intelligence
About Tearline
- Chatpilot – An intent-centric AI chatbot deployed on BNB Chain, Sui and TON, streamlining user onboarding and on-chain actions via natural language.
- GhostDriver – An execution-focused agent that automates web-based tasks across both Web2 and Web3 environments.
- FlowAgent – A newly launched task orchestrator enabling multi-agent coordination and smart contract execution.
Website: tearline.io
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Dr. Christopher E. Touloukian Reaches 2,367 Citations on ResearchGate for Pioneering Cancer Immunotherapy Research
Massachusetts, US, 6th July 2025, ZEX PR WIRE, Dr. Christopher E. Touloukian, a board-certified surgical oncologist and general surgeon, has officially surpassed 2,367 citations on ResearchGate, a leading platform for academic publishing and peer collaboration. This milestone reflects Dr. Touloukian’s enduring contributions to the field of cancer immunotherapy and underscores the global influence of his two-decade-long commitment to improving cancer treatment through rigorous research and surgical innovation.
A Career Built on Translational Excellence
Dr. Touloukian’s path in medicine began with his graduation from Columbia University College of Physicians and Surgeons, one of the most prestigious medical schools in the country. He then completed rigorous general surgery training at Yale University and Duke University, where he honed his technical skill and deepened his understanding of complex oncologic conditions.
Following his residency, Dr. Touloukian earned coveted fellowship positions in Surgical Oncology and Immunotherapy at the National Cancer Institute (NCI) and the National Institutes of Health (NIH). It was there that his interest in tumor immunology took firm root. Immersed in one of the world’s most advanced cancer research environments, he began developing the scientific foundation for what would become a lifelong mission: to integrate immune-based strategies into clinical cancer care.
A Milestone That Reflects Global Impact
The 2,367 citations on ResearchGate represent more than numbers. They illustrate thebreadth of Dr. Touloukian’s impact in scientific literature and the trust placed in his work by researchers, clinicians, and academic institutions worldwide. His research spans a range of high-stakes topics within oncology, including tumor-specific T-cell activation, immune checkpoint modulation, antigen presentation, interferon signaling, and the tumor microenvironment.
His most cited publications explore how tumors evade immune surveillance and how novel immunotherapies can restore or enhance immune responses. Among them are key contributions to our understanding of how CD8+ and CD4+ T cells coordinate to target malignancies, and how certain tumor antigens might be used in vaccine development. His work has appeared in respected journals including Cancer Research, The Journal of Immunology, and Nature Medicine.
Surgical Precision Meets Research Rigor
What distinguishes Dr. Touloukian is his ability to apply groundbreaking scientific insight to real-world clinical practice. As a surgical oncologist, he regularly manages complex cases involving gastrointestinal cancers, soft tissue sarcomas, and cutaneous malignancies. He treats patients across multiple states, holding active medical licenses in New York, Massachusetts, and Florida.
Whether he is in the operating room or consulting with colleagues on a multidisciplinary cancer board, Dr. Touloukian brings a research-informed approach to decision-making. He believes that every cancer case presents not only a surgical challenge but also an opportunity to apply or test the latest evidence-based therapies. This perspective has helped improve outcomes and has positioned him as a trusted authority in high-acuity medical settings.
Academic Leadership and Mentorship
Dr. Touloukian’s commitment to education is another key pillar of his career. He has served as a faculty member at Indiana University School of Medicine in the Department of Microbiology and Immunology. There, he mentored both medical students and researchers, helping guide the next generation of clinician-scientists.
His teachings emphasize the importance of questioning assumptions, applying rigorous methodology, and never losing sight of the patient behind the protocol. His dual role as a practicing surgeon and active researcher enables him to offer students a comprehensive view of how science and medicine can work together in service of better care.
Recognition from Peers and Foundations
In 2010, Dr. Touloukian was named a V Scholar by the V Foundation for Cancer Research. This competitive award recognizes promising physician-scientists conducting innovative cancer research at a national level. The award served as both validation and fuel for Dr. Touloukian’s continued investigations into immune modulation, antigen engineering, and therapeutic resistance mechanisms.
In the years since receiving the V Scholar award, Dr. Touloukian has published over 25 scientific papers and contributed to numerous collaborative projects. His work has not only earned citations but also inspired new research directions and clinical trials. Several of his
studies have informed current immunotherapy protocols and biomarker strategies now used in hospitals and research centers across the United States.
The Power of Peer Collaboration
The visibility and engagement Dr. Touloukian has achieved on ResearchGate also speak to his collaborative spirit. The platform has allowed him to share findings, respond to inquiries, and participate in global scientific dialogue. His profile is a living archive of progress in tumor immunology, where researchers can track both published works and the evolving ideas that shape them.
By making his work accessible, Dr. Touloukian invites others to build on his research, test new hypotheses, and refine therapeutic strategies. This openness accelerates discovery and helps ensure that findings move from the page to the patient as efficiently as possible.
Future Directions: From Lab to Life
Despite this significant citation milestone, Dr. Touloukian remains focused on what liesahead. He is currently involved in several projects exploring the next generation of immunotherapeutic approaches, including T-cell engineering, antigen-specific vaccine development, and the role of regulatory T cells in immune suppression.
He also continues to study how the tumor microenvironment influences treatment resistance, with the goal of finding new ways to disrupt the protective barriers that tumors build against the immune system. His future research will likely continue to bridge lab science and patient care, with an eye toward therapies that are not only effective but also tailored to the biology of each individual’s disease.
More Than Metrics: A Career Guided by Purpose
While the citation count offers a tangible measure of scientific impact, it does not capture the full story of Dr. Touloukian’s career. Behind every publication is a deep sense of purpose, a desire to make cancer less formidable, and a belief in the potential of science to change lives.
Colleagues describe him as both brilliant and approachable, someone who brings the same energy to a late-night research meeting as he does to a difficult surgical case. Patients see in him not just a doctor, but an advocate who listens, informs, and fights alongside them.
His journey is not only about discovery, but about translation — taking complex ideas and turning them into actionable treatments. This approach continues to resonate throughout his academic work, clinical practice, and mentorship.
A Legacy Still in Motion
As he surpasses 2,367 citations on ResearchGate, Dr. Christopher E. Touloukian’s influence is as dynamic as the field he helps shape. His work stands at the frontier of medicine, where science meets humanity, and where data becomes healing. For those who know him, this milestone is no surprise — it is simply another step in a career defined by excellence, empathy, and an unwavering commitment to making cancer care smarter and more hopeful.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
LF Labs’ July 30 Listing Blitz: The Catalyst That Could Propel LF Coin to $1
Dr. Christopher E. Touloukian Reaches 2,367 Citations on ResearchGate for Pioneering Cancer Immunotherapy Research
Introducing Tearline’s FlowAgent: A Modular AI Agent Bridging the Execution Trust Gap
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Microsoft License Enables Organizations to Navigate the Evolving Digital Landscape Through Customized Microsoft Solutions
-
Press Release1 week ago
AIDAv2 The Future of Investment in the Age of AI and How Its Shaping a New Financial Paradigm
-
Press Release1 day ago
Pichai Applauds Record-Breaking Success of THAIFEX – ANUGA ASIA 2025 Over 142,000 Visitors and Trade Value Surpassing 135 Billion Baht
-
Press Release1 week ago
Abrdn Grubu Leads the Future of Finance with AI and Technology Integration
-
Press Release1 week ago
Cloud mining giant FansHash Launches free and efficient cloud mining applications to easily improve mining efficiency and achieve simple operation
-
Press Release1 week ago
Nanolite Foundation Pioneering the Future of Technology Investment and Social Impact
-
Press Release6 days ago
Nectaren Embraces Sentimental Shopping Trends with Symbolic Story-Driven Products
-
Press Release6 days ago
DragonPro Unveils First Fully Autonomous AI Crypto Trading Platform
-
Press Release4 days ago
Atelier Home Sets a New Standard for Luxury Home Decor